GlaxoSmithKline PLC's majority-owned ViiV Healthcare is buying a raft of novel late-stage and early stage HIV assets from Bristol-Myers Squibb Co which it hopes will offer new options for patients who have outlived the utility of other antiretrovirals, thereby expanding ViiV's pipeline and future product sales.
GlaxoSmithKline PLC's majority-owned ViiV Healthcare is buying a raft of novel late-stage and early stage HIV assets from Bristol-Myers Squibb Co which it hopes will offer new options for patients who have outlived the utility of other antiretrovirals, thereby expanding ViiV's pipeline and future product sales.
As patients live longer and better with the HIV virus, many are outlasting the utility of various drugs and combination...
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
